Recent advances in β-thalassemia

Andreas E. Kulozik, MD, PhD, Hopp-Children’s Cancer Research Center (KiTZ), University of Heidelberg, Heidelberg, Germany, gives an overview of the latest advances in β-thalassemia, including developments in gene therapy and gene editing, as well as the introduction of new drugs such as luspatercept, which have been shown to improve hemoglobin levels and reduce transfusion requirements. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.